These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 29739427)

  • 1. Open innovation and external sources of innovation. An opportunity to fuel the R&D pipeline and enhance decision making?
    Schuhmacher A; Gassmann O; McCracken N; Hinder M
    J Transl Med; 2018 May; 16(1):119. PubMed ID: 29739427
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changing R&D models in research-based pharmaceutical companies.
    Schuhmacher A; Gassmann O; Hinder M
    J Transl Med; 2016 Apr; 14(1):105. PubMed ID: 27118048
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Schrödinger's pipeline and the outsourcing of pharmaceutical innovation.
    McMeekin P; Lendrem DW; Lendrem BC; Pratt AG; Peck R; Isaacs JD; Jones D
    Drug Discov Today; 2020 Mar; 25(3):480-484. PubMed ID: 31835019
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Accessing external innovation in drug discovery and development.
    Tufféry P
    Expert Opin Drug Discov; 2015 Jun; 10(6):579-89. PubMed ID: 25910932
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Powered by Open Innovation: Opportunities and Challenges in the Pharma Sector.
    Martinez-Grau MA; Alvim-Gaston M
    Pharmaceut Med; 2019 Jun; 33(3):193-198. PubMed ID: 31933287
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Open innovation platforms to boost pharmaceutical collaborations: evaluating external compounds for desired biological activity.
    Nilsson N; Felding J
    Future Med Chem; 2015; 7(14):1853-9. PubMed ID: 26393392
    [No Abstract]   [Full Text] [Related]  

  • 7. Models for open innovation in the pharmaceutical industry.
    Schuhmacher A; Germann PG; Trill H; Gassmann O
    Drug Discov Today; 2013 Dec; 18(23-24):1133-7. PubMed ID: 23892183
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Racing to define pharmaceutical R&D external innovation models.
    Wang L; Plump A; Ringel M
    Drug Discov Today; 2015 Mar; 20(3):361-70. PubMed ID: 25448753
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Crowd-sourcing delivery system innovation: A public-private solution.
    Agrawal S; Chen C; Tanio CP
    Healthc (Amst); 2015 Mar; 3(1):2-4. PubMed ID: 26179583
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Crowdsourcing in pharma: a strategic framework.
    Bentzien J; Bharadwaj R; Thompson DC
    Drug Discov Today; 2015 Jul; 20(7):874-83. PubMed ID: 25637169
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Open innovation: A paradigm shift in pharma R&D?
    Schuhmacher A; Gassmann O; Bieniok D; Hinder M; Hartl D
    Drug Discov Today; 2022 Sep; 27(9):2395-2405. PubMed ID: 35643258
    [TBL] [Abstract][Full Text] [Related]  

  • 12. On strategic choices faced by large pharmaceutical laboratories and their effect on innovation risk under fuzzy conditions.
    Puente J; Gascon F; Ponte B; de la Fuente D
    Artif Intell Med; 2019 Sep; 100():101703. PubMed ID: 31607342
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Open innovation in early drug discovery: roadmaps and roadblocks.
    Reichman M; Simpson PB
    Drug Discov Today; 2016 May; 21(5):779-88. PubMed ID: 26743597
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Measuring the effectiveness and impact of an open innovation platform.
    Carroll GP; Srivastava S; Volini AS; Piñeiro-Núñez MM; Vetman T
    Drug Discov Today; 2017 May; 22(5):776-785. PubMed ID: 28137644
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hurdles in tissue engineering/regenerative medicine product commercialization: a pilot survey of governmental funding agencies and the financial industry.
    Bertram TA; Tentoff E; Johnson PC; Tawil B; Van Dyke M; Hellman KB
    Tissue Eng Part A; 2012 Nov; 18(21-22):2187-94. PubMed ID: 22838399
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Open Innovation in Medical and Pharmaceutical Research: A Literature Landscape Analysis.
    Yeung AWK; Atanasov AG; Sheridan H; Klager E; Eibensteiner F; Völkl-Kernsock S; Kletecka-Pulker M; Willschke H; Schaden E
    Front Pharmacol; 2020; 11():587526. PubMed ID: 33519448
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Industrial Investment Funds, Government R&D Subsidies, and Technological Innovation: Evidence From Chinese Companies.
    Ren YM
    Front Psychol; 2022; 13():890208. PubMed ID: 35774961
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Private versus social incentives for pharmaceutical innovation.
    González P; Macho-Stadler I; Pérez-Castrillo D
    J Health Econ; 2016 Dec; 50():286-297. PubMed ID: 26944633
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmaceutical portfolio management: global disease burden and corporate performance metrics.
    Daems R; Maes E; Mehra M; Carroll B; Thomas A
    Value Health; 2014 Sep; 17(6):732-8. PubMed ID: 25236997
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Crowdsourcing and open innovation in drug discovery: recent contributions and future directions.
    Thompson DC; Bentzien J
    Drug Discov Today; 2020 Dec; 25(12):2284-2293. PubMed ID: 33011343
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.